---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-023665"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:25:43.625941+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio and uBriGene withdraw and re-file CFIUS notice; new 45-day review period begins Feb 13

## Summary
- On Feb 12, 2024, CFIUS granted request to withdraw and re-file the joint voluntary notice for the transaction.
- New 45-day review period started Feb 13, 2024, concluding no later than March 28, 2024.
- If CFIUS does not conclude by March 28, the proceeding will transition to a second 45-day investigation phase.
- The CFIUS review relates to Mustang's sale of its Worcester cell processing facility and associated assets to uBriGene.
- CFIUS clearance was not a condition to closing the transaction, but is being pursued voluntarily.

## SEC filing metadata
- accession: 0001104659-24-023665
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000110465924023665/0001104659-24-023665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000110465924023665/tm246262d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-023665
- JSON: https://secwatch.observer/filing/0001104659-24-023665.json
- Plain text: https://secwatch.observer/filing/0001104659-24-023665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.